Log in

NASDAQ:NVCR - Novocure Stock Price, Forecast & News

$87.00
-0.29 (-0.33 %)
(As of 01/28/2020 08:00 AM ET)
Today's Range
$83.29
Now: $87.00
$88.50
50-Day Range
$74.97
MA: $84.68
$95.65
52-Week Range
$41.51
Now: $87.00
$98.84
Volume824,966 shs
Average Volume1.07 million shs
Market Capitalization$8.61 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$248.07 million
Book Value$1.21 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

EmployeesN/A
Market Cap$8.61 billion
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.07. The medical equipment provider had revenue of $92.06 million for the quarter, compared to analysts' expectations of $87.12 million. Novocure had a negative return on equity of 18.45% and a negative net margin of 8.43%. The firm's quarterly revenue was up 42.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.13) EPS. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Novocure.

How can I listen to Novocure's earnings call?

Novocure will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Novocure issued on next quarter's earnings?

Novocure updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

What price target have analysts set for NVCR?

6 brokers have issued 12-month price objectives for Novocure's stock. Their forecasts range from $50.00 to $97.00. On average, they expect Novocure's stock price to reach $80.33 in the next twelve months. This suggests that the stock has a possible downside of 7.7%. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Has Novocure been receiving favorable news coverage?

Media headlines about NVCR stock have been trending somewhat negative on Tuesday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novocure earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Novocure.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

Who are Novocure's major shareholders?

Novocure's stock is owned by many different of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.35%), California Public Employees Retirement System (0.24%), Peregrine Capital Management LLC (0.15%), Taylor Frigon Capital Management LLC (0.04%), Strs Ohio (0.03%) and Polianta Ltd (0.01%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Janney Montgomery Scott LLC and Peregrine Capital Management LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

Which major investors are buying Novocure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Rhenman & Partners Asset Management AB, Sciencast Management LP, CWM LLC, Campbell & CO Investment Adviser LLC, Columbus Circle Investors, Polianta Ltd and Strs Ohio. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $87.00.

How big of a company is Novocure?

Novocure has a market capitalization of $8.61 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com/.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  377 (Vote Underperform)
Total Votes:  775
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel